Dear Editor,
We would like to thank Canpolat et al. for their interest in our article [1] . They pointed out that mean platelet volume (MPV) should be evaluated together with other inflammatory markers and that the results of the current study should be combined and endorsed with clinical outcomes like systemic embolization. These are indeed valid suggestions. In our study, we did not measure inflammatory markers, but we did exclude inflammatory diseases that could influence MPV such as rheumatic diseases. We also did 392 not investigate the prognostic value of MPV. We aimed only to assess its diagnostic value and any changes in MPV values after treatment.
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In a previous study, Gunebakmaz et al. [2] found that MPV was significantly higher in patients with observed embolic and other complications and death. They presumed that inflammation might cause procoagulant changes in platelet activity and that this inflammation-induced hypercoagulability might lead to embolization, one of the major causes of death. Other studies on patients with infective endocarditis showed that the normalization of inflammatory markers with antimicrobial therapy predicted a favorable outcome regarding surgery and death [3, 4] . Recently, Turak et al. [5] found that a high neutrophil-to-lymphocyte ratio at admission is an independent predictor of in-hospital mortality and nervous system events in patients with infective endocarditis.
We therefore agree that it would be useful to evaluate changes in MPV along with other inflammatory markers as a prognostic indicator of MPV in infective endocarditis.
